ClinicalTrials.gg
CompletedNCT03568656Updated Sep 25, 2026Results posted

Study to Evaluate CCS1477 in Advanced Tumours

A Phase 1/2 interventional study of CCS1477 and Abiraterone acetate in Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer and Non-small Cell Lung Cancer, sponsored by CellCentric Ltd.. Completed at 19 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by CellCentric Ltd. · Phase 1/2, Interventional, and Treatment

Updated Sep 25, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
219
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 757 studies in Breast Neoplasms with a site in United Kingdom — 98 open to participants now, 196 under way, 67 of them phase 3. Breast Neoplasms · United Kingdom.

Enrollment
309th of 613
219 · median 221
Started
2018
with 31 others
Phase 1/2
61 of 757
12 open now
Registered
488th of 757
by date

Among the 757 studies in Breast Neoplasms with a site in United Kingdom, this one is the 309th largest by enrollment of the 613 interventional ones that give a count, is one of 32 that started in 2018, is one of 61 in phase 1/2, and was the 488th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

98 of the 757 studies in Breast Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 757 studies in Breast Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

Read the detailed description

The Steering Committee closed selected cohorts, in accordance with its responsibilities, after findings from earlier cohorts indicated that further evaluation of those cohorts was no longer warranted. The remaining cohorts were completed as specified in the protocol. Therefore, the study was considered completed.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Breast Cancer
  • Non-small Cell Lung Cancer
  • Advanced Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of consent
  • performance status 0-1
  • Assessable disease (by CT, MRI, bone scan or X-ray)
  • Adequate organ function
  • Highly effective measures for duration of study

Additional inclusion criteria for mCRPC patients only:

  • Previously received abiraterone and/or enzalutamide (or equivalent anti-androgen), and docetaxel (unless ineligible or refused)
  • Progressive disease documented by one or more of the following:

    • Biochemical progression defined as at least 2 stepwise increases in a series of any 3 PSA values
    • Progression as defined by v1.1 guideline for assessment of malignant soft tissue disease.
    • Progression defined as two or more new bone lesions confirmed on bone scan from a previous assessment
  • PSA at screening ≥2 μg/L
  • Serum testosterone concentration ≤50 ng/dL
  • Serum albumin >2.5 g/dL

Additional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:

  • Patients must have previously progressed on abiraterone treatment
  • Patients whose last dose of abiraterone is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with abiraterone to confirm refractoriness to abiraterone treatment

Additional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:

  • Patients must have previously progressed on enzalutamide treatment
  • Patients whose last dose of enzalutamide is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with enzalutamide to confirm refractoriness to enzalutamide treatment

Additional inclusion criteria for patients in mutation arm:

  • Advanced solid tumour with identification of markers which may indicate potential for response to p300/CBP inhibition. Markers include loss of function mutations in CREBBP, EP300 or ARID1A, MYC gene amplifications or rearrangements and androgen receptor (AR) gene amplifications or over-expression.

Exclusion criteria

Exclusion Criteria:

  • Intervention with any chemotherapy, agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
  • Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks of the first dose of study treatment
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
  • Strong inhibitors of or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
  • Statins; patients should discontinue statins prior to starting study treatment
  • Any unresolved reversible toxicities from prior therapy > grade 1 at the time of starting study treatment
  • Any evidence of severe or uncontrolled systemic diseases
  • Any known uncontrolled inter-current illness
  • prolongation (> 480 msec).
  • Primary brain tumours or known or suspected .

Additional exclusion criteria for patients in CCS1477 plus abiraterone combination arm:

  • cardiac abnormalities

Additional exclusion criteria for patients in CCS1477 plus enzalutamide combination arm:

  • History of seizures or other predisposing factors
  • Use of substrates with a narrow therapeutic index metabolised by CYP2C9 or CYP2C19 within 2 weeks of the first dose of study treatment
  • Clinically significant cardiac abnormalities
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    CCS1477 dose escalation - mCRPC

    CCS1477 monotherapy in patients with mCRPC

    Drug: CCS1477

  • Experimental
    CCS1477 expansion phase - mCRPC

    CCS1477 monotherapy in patients with mCRPC

    Drug: CCS1477

  • Experimental
    CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC

    CCS1477 plus abiraterone acetate in patients with mCRPC

    Drug: CCS1477 · Drug: Abiraterone acetate

  • Experimental
    CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC

    CCS1477 plus enzalutamide in patients with mCRPC

    Drug: CCS1477 · Drug: Enzalutamide

  • Experimental
    CCS1477 Monotherapy - Solid tumours

    CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition

    Drug: CCS1477

  • Experimental
    CCS1477 and darolutamide, combination dose finding and expansion - mCRPC

    CCS1477 plus darolutamide in patients with mCRPC

    Drug: CCS1477 · Drug: Darolutamide

  • Experimental
    CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer

    CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.

    Drug: CCS1477 · Drug: Olaparib

  • Experimental
    CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer

    CCS1477 plus atezolizumab in patients with non-small cell lung cancer

    Drug: CCS1477 · Drug: Atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Withdrawal

    Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study intervention, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs were defined as those events with onset dates/time occurring after study intervention administration or events that worsen after study intervention administration. TEAEs included serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to withdrawal of study intervention was also reported.

    Time frame: From signing informed consent until the end of the follow-up period (Up to 363 weeks)

  2. Number of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

    Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in hematology according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.

    Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)

  3. Number of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

    Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in biochemistry according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.

    Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)

  4. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis

    The urinalysis measurements included glucose, protein and blood. Number of participants with clinically significant changes from baseline in urinalysis values were reported. Clinically Significance was decided by investigator.

    Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    The vital signs measurements included blood pressure, heart rate, respiration rate and temperature. Number of participants with clinically significant changes from baseline in vital signs values were reported. Clinically Significance was decided by investigator.

    Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)

  6. Number of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

    Twelve-lead Electrocardiograms (ECGs) were obtained after the participant was in semi-supine for 5 minutes. Three ECGs were taken at each timepoint at about 1-minute intervals. QTcF was calculated using the Fridericia formula: QTcF = QT ÷ RR\^(1/3), where QT is the measured QT interval in milliseconds and RR is the interval between two consecutive R waves on the ECG expressed in seconds. It was categorized as less than equal to (\<=) 450 milliseconds (msec), more than (\>) 450 to \<=480 msec, \> 480 to \<= 500 msec and \> 500 msec.

    Time frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)

Secondary outcomes

  1. Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

    Best percentage change from baseline was defined as the largest percentage reduction in PSA levels or the smallest percentage increase in PSA levels in the absence of a reduction.

    Time frame: At Baseline - Cycle 1 - Day 1, Day 8, Day 15, Day 22 and Day 1 of every cycle from cycle 2 onwards until treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)

  2. Number of Participants With CTC Response

    CTC response was defined as a change from unfavourable (five or more cells per 7.5 mL of blood) at baseline to favourable (four or fewer cells per 7.5 mL) post treatment. Number of participants with overall response were reported. A participant was determined as having an overall CTC response if they had at least one post baseline assessment of 'CTC response'.

    Time frame: From Baseline - Day 1 Cycle 1 (Predose), Day 1 Cycle 2, Day 1 Cycle 3, Day 1 Cycle 5 up to disease progression or treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)

  3. Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Objective response is defined as any participant with measurable disease who has a best overall response of Partial Response (PR) or Complete Response (CR). CR is defined as the disappearance of all Target Lesions (TLs) since baseline. PR is defined as At least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters.

    Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)

  4. Radiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Radiological progression free survival (rPFS) was defined as the time from the start of treatment with CCS1477 in Cycle 1 until the earliest objective disease progression defined by RECIST 1.1, Prostate Cancer Clinical Trial Working Group 3 (PCWG-3) bone progression or death by any cause in the absence of progression, regardless of whether the participants withdraws from study medication or receives another anti-cancer therapy prior to progression. Kaplan - Meier estimate was used to calculate the rPFS.

    Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)

  5. Overall Survival (OS)

    Overall survival is defined as the time from the start of treatment with CCS1477 in Cycle 1 until death due to any cause.

    Time frame: From start of treatment until death (Up to 363 weeks)

  6. Maximum Observed Plasma Concentration (Cmax)

    Cmax was obtained directly from concentration versus time curve.

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)

  7. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)

    AUC0-24 is defined as the area under the concentration-time curve (AUC) from time zero (= dosing time) to 24 hours. AUC0-24 was calculated using the mixed log-linear trapezoidal rule.

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)

07

Results

Posted Sep 25, 2026

Participant flow

The Steering Committee closed selected cohorts, in accordance with its responsibilities, after findings from earlier cohorts indicated that further evaluation of those cohorts was no longer warranted. The remaining cohorts were completed as specified in the protocol. Therefore, the study was considered completed.

Participant flow — Overall Study
MilestonePart A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg, BDPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
Started448488666457558222158779236541161620447
Completed000000000000000000000000000000000000
Not completed448488666457558222158779236541161620447
Withdrew: Abiraterone/enzalutamide responder000000000000000000000231000000000000
Withdrew: Death43847866544655622213765513444116911304
Withdrew: Lost to follow-up000010000000001000010000000000022000
Withdrew: Study terminated by sponsor000000000000001000200000000000036000
Withdrew: Other010000001011000000001010021000021143

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Withdrawal

Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study intervention, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs were defined as those events with onset dates/time occurring after study intervention administration or events that worsen after study intervention administration. TEAEs included serious TEAEs and non-serious TEAEs. Number of participants with TEAEs leading to withdrawal of study intervention was also reported.

Time frame:
From signing informed consent until the end of the follow-up period (Up to 363 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Withdrawal
ParticipantsPart A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
TEAEs438487666457552222387682365411636447
SAEs41534411123304111653110211000117115
TEAEs leading to withdrawal of CCS14772041130000000000112301000000002002
PrimaryNumber of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in hematology according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.

Time frame:
From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Reported as:
Count of participants · Participants
Number of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Platelets, Grade 0 to Grade 124521102
Platelets, Grade 0 to Grade 2400200
Platelets, Grade 0 to Grade 3300000
Platelets, Grade 0 to Grade 4300000
Platelets, Grade 1 to Grade 2200000
Platelets, Grade 1 to Grade 3200000
Platelets, Grade 1 to Grade 4100000
Eosinophils, Grade 0 to Grade 121312032
Neutrophils, Grade 0 to Grade 1400110
Neutrophils, Grade 0 to Grade 2100000
Neutrophils, Grade 0 to Grade 3100000
Neutrophils, Grade 1 to Grade 2100000
PrimaryNumber of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death related to the adverse event. Number of participants with worst shift in biochemistry according to Common Terminology Criteria for Adverse Events (CTCAE) grades were reported.

Time frame:
From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Reported as:
Count of participants · Participants
Number of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Albumin, Grade 0 to Grade 11225712
Albumin, Grade 0 to Grade 21000301
Albumin, Grade 1 to Grade 2003111
Alkaline Phosphatase, Grade 0 to Grade 12527321
Alkaline Phosphatase, Grade 0 to Grade 2413100
Alkaline Phosphatase, Grade 0 to Grade 3101001
Alanine Aminotransferase, Grade 0 to Grade 11200702
Alanine Aminotransferase, Grade 0 to Grade 2000100
Aspartate Aminotransferase, Grade 0 to Grade 125441122
Aspartate Aminotransferase, Grade 0 to Grade 2100101
Aspartate Aminotransferase, Grade 0 to Grade 3000100
Creatinine, Grade 0 to Grade 11324512
Creatinine, Grade 0 to Grade 21801311
Creatinine, Grade 0 to Grade 3300000
Creatinine, Grade 0 to Grade 4000100
Creatinine, Grade 1 to Grade 2300000
Creatinine, Grade 2 to Grade 3100000
Lactate Dehydrogenase, Grade 0 to Grade 13569942
Total Bilirubin, Grade 0 to Grade 1714301
Total Bilirubin, Grade 0 to Grade 2200200
Total Bilirubin, Grade 0 to Grade 3201000
Total Bilirubin, Grade 0 to Grade 4000200
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis

The urinalysis measurements included glucose, protein and blood. Number of participants with clinically significant changes from baseline in urinalysis values were reported. Clinically Significance was decided by investigator.

Time frame:
From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - Urinalysis000000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

The vital signs measurements included blood pressure, heart rate, respiration rate and temperature. Number of participants with clinically significant changes from baseline in vital signs values were reported. Clinically Significance was decided by investigator.

Time frame:
From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Number of Participants With Clinically Significant Change From Baseline in Vital Signs000000
PrimaryNumber of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades

Twelve-lead Electrocardiograms (ECGs) were obtained after the participant was in semi-supine for 5 minutes. Three ECGs were taken at each timepoint at about 1-minute intervals. QTcF was calculated using the Fridericia formula: QTcF = QT ÷ RR\^(1/3), where QT is the measured QT interval in milliseconds and RR is the interval between two consecutive R waves on the ECG expressed in seconds. It was categorized as less than equal to (\<=) 450 milliseconds (msec), more than (\>) 450 to \<=480 msec, \> 480 to \<= 500 msec and \> 500 msec.

Time frame:
From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Reported as:
Count of participants · Participants
Number of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 Grades
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
<= 450 msec to > 450 - <= 480 msec2029422
<= 450 msec to > 480 - <= 500 msec112100
<= 450 msec to > 500 msec100400
> 450 - <= 480 msec to > 480 - <= 500 msec102001
> 450 - <= 480 msec to > 500 msec202000
SecondaryBest Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Best percentage change from baseline was defined as the largest percentage reduction in PSA levels or the smallest percentage increase in PSA levels in the absence of a reduction.

Time frame:
At Baseline - Cycle 1 - Day 1, Day 8, Day 15, Day 22 and Day 1 of every cycle from cycle 2 onwards until treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
Reported as:
Mean · percentage change from baseline
Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
percentage change from baselinePart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart F1: CCS1477 in Combination With Darolutamide
Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)5.39 ± 35.650-8.88 ± 39.560-2.85 ± 27.712-0.89 ± 30.687
SecondaryNumber of Participants With CTC Response

CTC response was defined as a change from unfavourable (five or more cells per 7.5 mL of blood) at baseline to favourable (four or fewer cells per 7.5 mL) post treatment. Number of participants with overall response were reported. A participant was determined as having an overall CTC response if they had at least one post baseline assessment of 'CTC response'.

Time frame:
From Baseline - Day 1 Cycle 1 (Predose), Day 1 Cycle 2, Day 1 Cycle 3, Day 1 Cycle 5 up to disease progression or treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Reported as:
Count of participants · Participants
Number of Participants With CTC Response
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 Monotherapy
Number of Participants With CTC Response6150
SecondaryObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Objective response is defined as any participant with measurable disease who has a best overall response of Partial Response (PR) or Complete Response (CR). CR is defined as the disappearance of all Target Lesions (TLs) since baseline. PR is defined as At least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters.

Time frame:
From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
ParticipantsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1110010
SecondaryRadiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Radiological progression free survival (rPFS) was defined as the time from the start of treatment with CCS1477 in Cycle 1 until the earliest objective disease progression defined by RECIST 1.1, Prostate Cancer Clinical Trial Working Group 3 (PCWG-3) bone progression or death by any cause in the absence of progression, regardless of whether the participants withdraws from study medication or receives another anti-cancer therapy prior to progression. Kaplan - Meier estimate was used to calculate the rPFS.

Time frame:
From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
Reported as:
Median · months
Radiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
monthsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Radiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.12.8 (1.9 to 3.5)1.9 (1.6 to 3.5)3.6 (1.9 to 5.5)1.9 (1.7 to 2.3)2.8 (1.9 to 8.4)2.9 (1.7 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the start of treatment with CCS1477 in Cycle 1 until death due to any cause.

Time frame:
From start of treatment until death (Up to 363 weeks)
Reported as:
Median · months
Overall Survival (OS)
monthsPart A and B1: CCS1477 MonotherapyPart C1: CCS1477 in Combination With AbirateronePart D1: CCS1477 in Combination With EnzalutamidePart E1 and E2: CCS1477 MonotherapyPart F1: CCS1477 in Combination With DarolutamidePart H1: CCS1477 in Combination With Atezolizumab
Overall Survival (OS)10.5 (9.30 to 12.00)14.2 (7.80 to 19.50)15.4 (10.90 to 17.10)10.2 (5.80 to 12.60)13.8 (13.70 to NA)7.2 (1.80 to NA)
SecondaryMaximum Observed Plasma Concentration (Cmax)

Cmax was obtained directly from concentration versus time curve.

Time frame:
Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
Reported as:
Geometric mean · nanogram/milliliter(ng/ml)
Maximum Observed Plasma Concentration (Cmax)
nanogram/milliliter(ng/ml)Part A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
Cycle 1 - Day 1708.4 ± 64.01434.1 ± 104.8823.1 ± 29.3628.5 ± 83.9485.7 ± 66.6375.5 ± 36.9132.1 ± 31.3237.6 ± 65.2303.7 ± 41.5351.4 ± 44.7132.6 ± 68.6968.6 ± 61.7515.4 ± 22.71462.9 ± 56.2682.9 ± 154.2820.0 ± 56.5893.7 ± 104.4557.5 ± 69.5248.0 ± 104.1522.4 ± 72.513484.5 ± 68.614717.1 ± 74.115440.9 ± 23.611271.5 ± 97.015420.6 ± 20.63449.1 ± 13.217843.4 ± 6.9259.1 ± 35.4344.3 ± 55.4301.0 ± 102.9427.1 ± 67.53838.6 ± 16.86140.8 ± 29.6702.8 ± 55.6
Cycle 2 - Day 3——813 ± NA—676.9 ± 58.5———531.5 ± 51.5545.9 ± 51.1—847.1 ± 55.6670.5 ± 21.01515.0 ± 46.61720.0 ± NA1160.0 ± NA—633.6 ± 71.6———16240.7 ± 4.8——19770.9 ± 32.316272.2 ± 7.2————————
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)

AUC0-24 is defined as the area under the concentration-time curve (AUC) from time zero (= dosing time) to 24 hours. AUC0-24 was calculated using the mixed log-linear trapezoidal rule.

Time frame:
Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)
hours*nanograms per milliliter (h*ng/mL)Part A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide, DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
Cycle 1 - Day 15750.4 ± 197.510447.9 ± 137.36755.0 ± 47.15944.7 ± 95.73790.5 ± 141.82542.0 ± 59.4829.2 ± 81.81572.1 ± 88.41776.1 ± 42.13697.1 ± 58.3646.4 ± 46.44195.7 ± 97.22096.7 ± 32.06594.1 ± 89.52873.6 ± 360.03247.1 ± 0.43732.8 ± 199.43299.2 ± 76.91218.1 ± 93.42492.1 ± 51.7249370.4 ± 98.4269964.2 ± 99.4292439.6 ± 14.3194471.6 ± 175.9308618.7 ± 20.338260.0 ± 25.9336943.2 ± 18.12891.8 ± NA3400.8 ± NA8460.4 ± 75.63561.3 ± 114.71334.9 ± 28.91852.9 ± 111.73686.0 ± 48.1
Cycle 2 - Day 3——9543.7 ± NA—————3103.8 ± 99.14385.7 ± 36.1—3582.3 ± 88.22813.0 ± 19.28822.0 ± 119.1———————310130.1 ± 24.6——339289.0 ± 37.0296836.3 ± 1.0————————

Adverse events

Collected over Up to end of study (Up to 363 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: CCS1477 100mg, Once Daily4/4 (100%)4/4 (100%)4/4 (100%)
Part A: CCS1477 100mg, 2/Week3/4 (75%)1/4 (25%)3/4 (75%)
Part A: CCS1477 100mg, 3 Days on and 4 Days Off8/8 (100%)5/8 (62.5%)8/8 (100%)
Part A: CCS1477 100mg, 3/Week4/4 (100%)3/4 (75%)4/4 (100%)
Part A: CCS1477 50mg BD, 3 Days on and 4 Days Off7/8 (87.5%)4/8 (50%)8/8 (100%)
Part A: CCS1477 50mg, Once Daily8/8 (100%)4/8 (50%)7/8 (87.5%)
Part A: CCS1477 25mg, BD6/6 (100%)1/6 (16.7%)6/6 (100%)
Part A: CCS1477 25 mg, Once Daily6/6 (100%)1/6 (16.7%)6/6 (100%)
Part A: CCS1477 50mg, 4 Days on and 3 Days Off5/6 (83.3%)1/6 (16.7%)6/6 (100%)
Part A: CCS1477 50mg, 5 Days on and 2 Days Off4/4 (100%)2/4 (50%)4/4 (100%)
Part A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days Off4/5 (80%)3/5 (60%)5/5 (100%)
Part A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off6/7 (85.7%)3/7 (42.9%)7/7 (100%)
Part A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days Off5/5 (100%)0/5 (0%)5/5 (100%)
Part A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days Off5/5 (100%)4/5 (80%)5/5 (100%)
Part A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off6/8 (75%)2/8 (25%)8/8 (100%)
Part A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days Off2/2 (100%)1/2 (50%)2/2 (100%)
Part A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days Off2/2 (100%)1/2 (50%)2/2 (100%)
Part A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days Off2/2 (100%)1/2 (50%)2/2 (100%)
Part B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off13/15 (86.7%)4/15 (26.7%)15/15 (100%)
Part C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days Off7/8 (87.5%)5/8 (62.5%)8/8 (100%)
Part C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days Off6/7 (85.7%)3/7 (42.9%)7/7 (100%)
Part D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off5/7 (71.4%)1/7 (14.3%)7/7 (100%)
Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days Off5/9 (55.6%)1/9 (11.1%)8/9 (88.9%)
Part D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days Off1/2 (50%)0/2 (0%)2/2 (100%)
Part D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide Daily3/3 (100%)2/3 (66.7%)3/3 (100%)
Part D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days Off4/6 (66.7%)1/6 (16.7%)5/6 (83.3%)
Part D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days Off4/5 (80%)1/5 (20%)5/5 (100%)
Part D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days Off4/4 (100%)0/4 (0%)4/4 (100%)
Part E1: CCS1477 50mg Daily, 4 Days on and 3 Days Off1/1 (100%)0/1 (0%)1/1 (100%)
Part E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days Off1/1 (100%)0/1 (0%)1/1 (100%)
Part E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days Off6/6 (100%)1/6 (16.7%)6/6 (100%)
Part E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off9/16 (56.3%)7/16 (43.8%)15/16 (93.8%)
Part E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days Off11/20 (55%)10/20 (50%)20/20 (100%)
Part F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off3/4 (75%)1/4 (25%)4/4 (100%)
Part F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days Off0/4 (0%)1/4 (25%)4/4 (100%)
Part H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off4/7 (57.1%)5/7 (71.4%)7/7 (100%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventPart A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg, BDPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
Back painMusculoskeletal and connective tissue disorders0/40/40/80/40/80/80/60/60/60/40/51/70/50/50/80/20/20/21/150/80/70/71/90/22/30/60/50/40/10/10/61/160/200/41/40/7
AnaemiaBlood and lymphatic system disorders1/40/40/80/40/80/80/60/60/60/40/50/70/50/50/80/21/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/41/40/7
ConstipationGastrointestinal disorders0/40/40/80/40/80/80/60/60/60/40/50/70/50/50/81/20/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/40/40/7
FatigueGeneral disorders and administration site conditions0/40/40/80/40/80/80/60/60/60/40/50/70/50/50/80/20/21/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/40/41/7
Urinary tract infectionInfections and infestations0/40/41/80/41/80/80/60/61/61/42/51/70/51/50/81/20/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/40/40/7
HyponatraemiaMetabolism and nutrition disorders2/40/41/80/41/81/80/60/60/60/40/50/70/50/50/80/20/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/40/40/7
Confusional statePsychiatric disorders0/40/40/80/41/80/80/60/60/60/40/50/70/50/50/81/20/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/161/200/40/40/7
Acute kidney injuryRenal and urinary disorders1/40/42/80/41/81/80/60/60/60/40/50/70/51/50/80/21/20/20/150/80/70/70/90/20/30/60/50/40/10/10/60/160/200/41/40/7
Pelvic painReproductive system and breast disorders0/40/40/80/40/80/80/60/60/60/40/50/70/50/50/80/20/21/21/150/81/70/70/90/20/30/60/50/40/10/10/60/160/200/40/40/7
Lower respiratory tract infectionInfections and infestations0/40/40/80/40/80/80/60/60/60/42/50/70/52/50/80/20/20/20/151/80/70/70/90/20/30/60/50/40/10/10/60/160/200/40/42/7
Most frequent other events
Showing 10 of 368
Most frequent other events
EventPart A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg, BDPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days Off
ThrombocytopeniaBlood and lymphatic system disorders1/40/41/82/42/80/82/61/62/61/40/52/70/52/56/81/20/20/23/150/83/70/71/90/20/31/61/50/40/11/11/64/162/200/40/42/7
Abdominal discomfortGastrointestinal disorders0/40/40/80/40/80/80/60/60/60/40/50/70/50/50/80/20/20/20/150/80/70/70/90/20/30/60/50/41/10/10/60/160/200/40/40/7
ConstipationGastrointestinal disorders4/41/43/81/42/82/81/61/61/62/40/54/70/52/51/80/20/20/26/153/85/73/70/90/22/30/63/51/41/11/11/63/163/201/40/45/7
DiarrhoeaGastrointestinal disorders1/40/43/81/41/81/82/61/62/61/42/53/72/52/53/81/21/20/26/150/82/74/70/90/22/32/60/50/41/11/12/65/163/201/42/42/7
GastritisGastrointestinal disorders0/40/40/80/40/80/80/60/60/60/40/50/70/50/50/80/20/20/20/150/80/70/70/90/20/30/60/50/41/10/10/60/161/200/40/40/7
NauseaGastrointestinal disorders3/40/44/80/46/84/82/62/62/61/40/53/74/52/50/81/21/21/23/152/84/73/73/90/21/32/62/54/40/11/13/65/163/201/42/45/7
VomitingGastrointestinal disorders2/40/42/81/43/81/80/60/60/62/42/50/71/50/50/81/20/20/23/152/81/71/71/90/21/30/62/51/40/11/11/66/162/202/41/44/7
FatigueGeneral disorders and administration site conditions1/41/43/83/43/84/82/62/62/62/44/55/74/54/54/80/22/21/27/154/86/73/75/91/23/33/65/53/41/11/13/64/165/203/43/45/7
Lower respiratory tract infectionInfections and infestations0/40/40/80/40/80/80/60/60/60/41/50/70/50/50/80/21/20/20/151/82/70/70/90/21/30/63/51/41/10/11/61/161/200/40/41/7
MastitisInfections and infestations0/40/40/81/40/80/80/60/60/60/40/50/70/50/50/80/20/20/20/150/80/70/70/90/20/30/60/50/40/11/10/60/160/200/40/40/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days OffTotal
Mean72.0 ± 6.2770.3 ± 10.8167.6 ± 6.4473.8 ± 3.3074.3 ± 6.8669.5 ± 8.7570.7 ± 8.2468.7 ± 9.0070.0 ± 2.8364.8 ± 6.9064.8 ± 3.4271.4 ± 5.7773.4 ± 4.9374.2 ± 6.8075.0 ± 4.2473.5 ± 0.7178.0 ± 1.4171.1 ± 6.4170.0 ± 4.5770.9 ± 7.2266.6 ± 6.0074.0 ± 5.5268.5 ± 3.5468.7 ± 12.0667.7 ± 5.3969.0 ± 9.1460.8 ± 5.1976.0 ± NA41.0 ± NA56.3 ± 14.8459.7 ± 12.5868.8 ± 4.1170.0 ± 2.7167.3 ± 15.4267.3 ± 15.42
Sex: Female, Male
Sex: Female, Male(Participants)Part A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days OffTotal
Female0000000000000000000000000000142400433
Male448488666457552222387792365410212443186
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: CCS1477 100mg, Once DailyPart A: CCS1477 100mg, 2/WeekPart A: CCS1477 100mg, 3 Days on and 4 Days OffPart A: CCS1477 100mg, 3/WeekPart A: CCS1477 50mg BD, 3 Days on and 4 Days OffPart A: CCS1477 50mg, Once DailyPart A: CCS1477 25mg BD, DailyPart A: CCS1477 25 mg, Once DailyPart A: CCS1477 50mg, 4 Days on and 3 Days OffPart A: CCS1477 50mg, 5 Days on and 2 Days OffPart A: CCS1477 (10mg-Modified Formulation/20mg-Modified Formulation) 50mg, 4 Days On and 3 Days OffPart A: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 30mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 75mg - Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 50mg BD-Modified Formulation, 4 Days on and 3 Days OffPart A: CCS1477 35mg BD-Modified Formulation, 10 Days on and 4 Days OffPart A: CCS1477 50mg OD-Modified Formulation, 10 Days on and 4 Days OffPart A and B1: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart C1: CCS1477 50mg-Modified Formulation in Combination With Abiraterone, 4 Days on and 3 Days OffPart C1: CCS1477 35mg-MF BD in Combination With Abiraterone, 4 Days on and 3 Days OffPart D1: CCS1477 50mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3 Days OffPart D1: CCS1477 100mg-Modified Formulation in Combination With Enzalutamide,4 Days on and 3Days OffPart D1: CCS1477 75mg-Modified Formulation in Combination With Enzalutamide DailyPart D1: CCS1477 75mg BD - MF in Combination With Enzalutamide, 4 Days on 3 Days OffPart D1: CCS1477 35mg and 75mg BD-MF in Combination With Enzalutamide, 4 Days on and 3 Days OffPart D1: CCS1477 50mg Daily-MF in Combination With Enzalutamide, 10 Days on and 4 Days OffPart E1: CCS1477 50mg Daily, 4 Days on and 3 Days OffPart E1: CCS1477 50mg-Modified Formulation, 4 Days on and 3 Days OffPart E1: CCS1477 75mg-Modified Formulation, 4 Days on and 3 Days OffPart E1 and E2: CCS1477 35mg BD-Modified Formulation, 4 Days on and 3 Days OffPart F1: CCS1477 25mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart F1: CCS1477 35mg BD-MF in Combination With Darolutamide, 4 Days on and 3 Days OffPart H1: CCS1477 25mg BD-MF in Combination With Atezolizumab, 4 Days on and 3 Days OffTotal
American Indian or Alaska Native00000000000000000000000000000000000
Asian00000110000000000000100100000031008
Native Hawaiian or Other Pacific Islander00000000000000000000000000000000000
Black or African American00000000000100000000000000000020003
White448487566456552222387692265411621346197
More than one race00000000000000000000000000000000000
Unknown or Not Reported0000000000000000000000000000001000111
08

Study locations

19 sites
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center
    Philadelphia, Pennsylvania 19107, United States
  • Institute Bergonie
    Bordeaux, 33000, France
  • Hôpital Europeen Georges Pompidou
    Paris, 75015, France
  • Institute Gustave Roussy
    Villejuif, 94805, France
  • Netherlands Cancer Institute (NKI)
    Amsterdam, 1066 CX, Netherlands
  • Hospital Vall d'Hebron, VHIO
    Barcelona, 08035, Spain
  • START CIOCC Hospital Universitario HM
    Madrid, 28050, Spain
  • Karolinska Institute
    Stockholm, 171 76, Sweden
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Queen Elizabeth Hospital Cancer Centre
    Birmingham, B15 2TH, United Kingdom
  • Cambridge University Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Edinburgh Cancer Centre Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • The Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • The Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Freeman Hospital
    Newcastle, NE7 7DN, United Kingdom
  • University Hospital Southampton
    Southampton, SO16 6YD, United Kingdom
  • Royal Marsden Hospital
    Sutton, SM2 5NG, United Kingdom
09

References and documents

Publications

  • Caligiuri M, Williams GL, Castro J, Battalagine L, Wilker E, Yao L, Schiller S, Toms A, Li P, Pardo E, Graves B, Azofeifa J, Chicas A, Herbertz T, Lai M, Basken J, Wood KW, Xu Q, Guichard SM. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. Target Oncol. 2023 Mar;18(2):269-285. doi: 10.1007/s11523-023-00949-7. Epub 2023 Feb 24. PubMed 36826464 ↗
  • Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153. PubMed 36125208 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2025, 83 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 83 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2018
First posted
Jun 26, 2018
StartActual
Jul 23, 2018
Primary completionActual
Jul 6, 2025
CompletionActual
Jul 6, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Enrollment
220→219
Sep 25, 2026
Primary outcomes
6 added, 2 removed
What changed in the outcomes
  • AddedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to WithdrawalTime frame: From signing informed consent until the end of the follow-up period (Up to 363 weeks)
  • AddedNumber of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
  • AddedNumber of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
  • AddedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - UrinalysisTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
  • AddedNumber of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
  • AddedNumber of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
  • RemovedIncidence of treatment-related adverse eventsTime frame: Up to 12 months
  • RemovedLaboratory assessmentsTime frame: Up to 12 months
Sep 25, 2026
Documents
Secondary outcomes
1 edited, 6 added, 5 removed
What changed in the outcomes
  • EditedNumber of Participants With CTC responseResponseTime frame: Up to 12 months → From Baseline - Day 1 Cycle 1 (Predose), Day 1 Cycle 2, Day 1 Cycle 3, Day 1 Cycle 5 up to disease progression or treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
  • AddedBest Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)Time frame: At Baseline - Cycle 1 - Day 1, Day 8, Day 15, Day 22 and Day 1 of every cycle from cycle 2 onwards until treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
  • AddedObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
  • AddedRadiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
  • AddedOverall Survival (OS)Time frame: From start of treatment until death (Up to 363 weeks)
  • AddedMaximum Observed Plasma Concentration (Cmax)Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
  • AddedArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
  • RemovedPSA responseTime frame: Up to 12 months
  • RemovedObjective response rate (ORR)Time frame: Up to 12 months
  • RemovedRadiological progression-free survival (rPFS)Time frame: Up to 12 months
  • RemovedAUC of CCS1477Time frame: Up to 30 days after first dose of CCS1477
  • RemovedCmax of CCS1477Time frame: Up to 30 days after first dose of CCS1477
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Enrollment 220→219
    Primary outcomes 6 added, 2 removed
    What changed in the outcomes
    • AddedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to WithdrawalTime frame: From signing informed consent until the end of the follow-up period (Up to 363 weeks)
    • AddedNumber of Participants With Worst Shift in Laboratory Data-Hematology According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
    • AddedNumber of Participants With Worst Shift in Laboratory Data-Biochemistry According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
    • AddedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters - UrinalysisTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
    • AddedNumber of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
    • AddedNumber of Participants With Worst Shift in QTcF According to Common Terminology Criteria for Adverse Events (CTCAE)-Version 5 GradesTime frame: From first dose of study drug in Cycle 1 up to and including 28 days after last dose of study intervention (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
    • RemovedIncidence of treatment-related adverse eventsTime frame: Up to 12 months
    • RemovedLaboratory assessmentsTime frame: Up to 12 months
    Secondary outcomes 1 edited, 6 added, 5 removed
    What changed in the outcomes
    • EditedNumber of Participants With CTC responseResponseTime frame: Up to 12 months → From Baseline - Day 1 Cycle 1 (Predose), Day 1 Cycle 2, Day 1 Cycle 3, Day 1 Cycle 5 up to disease progression or treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
    • AddedBest Percentage Change From Baseline in Prostate Specific Antigen (PSA) Response in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)Time frame: At Baseline - Cycle 1 - Day 1, Day 8, Day 15, Day 22 and Day 1 of every cycle from cycle 2 onwards until treatment discontinuation (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles.)
    • AddedObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
    • AddedRadiological Progression Free Survival (rPFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From day of study intervention in Cycle 1 until progression or censoring date in the absence of progression (Up to 363 weeks) (Cycle length was 4 weeks for Cycles 1-6 and 6 weeks for Cycle 7 and subsequent cycles)
    • AddedOverall Survival (OS)Time frame: From start of treatment until death (Up to 363 weeks)
    • AddedMaximum Observed Plasma Concentration (Cmax)Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
    • AddedArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-24)Time frame: Cycle 1 Day 1 and Cycle 2 Day 3 (Cycle length was 4 weeks)
    • RemovedPSA responseTime frame: Up to 12 months
    • RemovedObjective response rate (ORR)Time frame: Up to 12 months
    • RemovedRadiological progression-free survival (rPFS)Time frame: Up to 12 months
    • RemovedAUC of CCS1477Time frame: Up to 30 days after first dose of CCS1477
    • RemovedCmax of CCS1477Time frame: Up to 30 days after first dose of CCS1477
    + 4 other changes: index terms, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03568656
Lead sponsor
CellCentric Ltd.
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Jul 23, 2018
Primary completion
Jul 6, 2025
Completion
Jul 6, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Johann de Bono, MD
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CCS1477

Start the discussion